Pricing Log in Create free account

Dermata Therapeutics, Inc. (DRMA) vs Nuvilex Inc. (PMCB)

Dermata Therapeutics, Inc. and Nuvilex Inc. are both Biotechnology companies. Dermata Therapeutics, Inc. and Nuvilex Inc. are of similar size ($4.0M and $3.8M). Across the 9 metrics below, Dermata Therapeutics, Inc. leads on 5 and Nuvilex Inc. on 4.

Valuation

Metric DRMA PMCB Biotechnology median
P/E n/m n/m 10.60
P/S n/m n/m 9.40
P/B 0.89 0.14 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.07 3.77 0.66
EV/Sales n/m n/m 9.02
Earnings yield (585.53%) (650.59%) (32.88%)
Free cash flow yield (259.42%) (266.52%) (23.13%)

Profitability

Metric DRMA PMCB Biotechnology median
Gross margin — 95.64% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (183.89%) (58.04%) (51.96%)
Return on assets (139.93%) (50.43%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric DRMA PMCB Biotechnology median
Revenue growth (TTM) — (71.06%) 6.76%
EPS growth (last fiscal year) 89.84% (186.83%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DRMA PMCB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.81 40.29 4.97
Net debt to EBITDA 0.97 5.41 1.01

Dividend

Metric DRMA PMCB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric DRMA PMCB Biotechnology median
Market cap 3.78m 4.03m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack